CCCC Stock Analysis: Buy, Sell, or Hold?
CCCC - C4 Therapeutics, Inc.
$3.18
-0.38 (-10.67%)
▼
5d:
+0.32%
30d:
+8.9%
90d:
+73.77%
BUY
MODERATE Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Smart Money Distribution
CCCC is up 15.4% this week, but smart money is buying puts. Top strike: $2 2026-07-17 with 244 OI. Put ratio: 62% View Scanner →
Strength: 8.9/10
Get Alerted When CCCC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
5 traders called CCCC this week
90% bullish • 1 bearish
90% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CCCC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CCCC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CCCC is currently trading at $3.18, which is considered slightly high relative to its 30-day fair value range of $2.72 to $3.26.
Technical Outlook: Technically, CCCC is in a strong uptrend. Immediate support is located at $2.79, while resistance sits at $3.95. Short-term momentum is weak, with the stock down 10.7% recently.
Market Sentiment: CCCC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.57 (+225.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CCCC is in a strong uptrend. Immediate support is located at $2.79, while resistance sits at $3.95. Short-term momentum is weak, with the stock down 10.7% recently.
Market Sentiment: CCCC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.57 (+225.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.72 -
$3.26
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.7%)
- BULLISH: Trading 225.0% below Wall St target ($11.57)
Trading Range Analysis
30-Day Trading Range
$2.72 -
$3.26
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.80
Resistance Level
$3.95
Current Trend
Strong Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.95
Wall Street Target
$11.57
(+225.0%)
Revenue Growth (YoY)
112.8%
Profit Margin
-292.1%
Share & Embed Analysis
Last updated: May 18, 2026 2:39 PM ET
Data refreshes hourly during market hours. Next update: 3:39 PM
Data refreshes hourly during market hours. Next update: 3:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CCCC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Leonard Reyno
SELL
10000 shares
2026-01-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 50 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 56 HOLD |
